Xenetic partners with University of Virginia to advance DNase platform
Xenetic has signed the research funding agreement and material transfer agreement with UVA to obtain an exclusive license…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Jan 24
Xenetic has signed the research funding agreement and material transfer agreement with UVA to obtain an exclusive license…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jan 24
Along with istaroxime, the agreement licences Windtree’s preclinical next-generation SERCA2a activators, called dual mechanism SERCA2a activators
18 Jan 24
The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in…
18 Jan 24
The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,…
17 Jan 24
The company is currently working towards obtaining approvals from institutional review boards (IRB) at the designated clinical trial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Jan 24
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed…
17 Jan 24
The WuXiBody platform enables almost any mAb sequence pairs to be assembled into bispecific constructs that are expected…
16 Jan 24
Armatus Bio’s lead candidate for CMT1A has received orphan drug designation and rare paediatric drug designation from the…
16 Jan 24
PanDNA is designed to expand the array of sample types suitable for long-read sequencing, including cells, bacteria, blood,…
16 Jan 24
The IMPROVE-2 study enrolled 904 women and assigned randomly to the new drug therapy group against a monthly…